TROG 16.03 CORE is a phase II, international, non-blinded, randomised controlled trial in patients with breast, prostate or non-small cell lung cancer (NSCLC) primary cancer to evaluate if the addition of stereotactic body radiotherapy (SBRT) to standard therapy improves progression-free survival outcomes in patients with extra-cranial metastases that have spread from either their lung, breast … Continue reading ALTG 16/011 TROG 16.03 CORE: Conventional care Or Radioablation for Extracranial metastases – F Foroudi/ D Pryor